.
The first study highlighted that few countries in Asia-Pacific have large AHDB, namely Australia, Japan, Singapore, • South Korea and Taiwan, and described these databases and their access. It is therefore of interest, in a second step, to examine how these AHDB are being used, notably for health economics purposes.
• To assess the use of AHDB in studies relevant to Health Economics and Outcomes Research (HEOR) concerning • the use of antidepressants (AD).
• A literature search was conducted to identify articles or posters related to topics of our interest.
• Sources: Embase® and MEDLINE® • Methodology: searched combined disease area (depression or antidepressants), topics of interest (pattern, • cost or resource use but NOT safety), database and country (see Table 1 ) Countries: Australia, Japan, Korea, Singapore and Taiwan Describing antidepressant prescription patterns, resource use or cost of depression from a AHDB of the • country of interest Both the number of studies as well as the topics of focus were described per country to identify the type of AHDB • research done in a given country and a qualitative comparison was made between countries.
INTRODUCTION

OBJECTIVES
METHODS
RESULTS -ARTICLES IDENTIFIED
Poster presented at the 6th Asia-Pacific Conference of the International Society for Pharmacoeconomics and Outcomes Research, 6-9 September 2014, Beijing, China
Viewed in the context of the earlier study on availability of accessibility of AHDB, it appears from our second phase • of research, that Australia and Taiwan have a high degree of usage of their national AHDB, considering both the number of publications and the broadness of subjects analysed within the 3 topics of interest of treatment pattern, resource use and costs. This may be due to some advantages in terms of database accessibility, transparency of processes and representativeness of the population. However, our findings reflect research done in the field of depression only and may not be representative of the work done on AHDB in general in these countries Based on this, the authors feel that, for the purpose of research and improving understanding of disease, the use • of Australia or Taiwan national database is a good example especially for countries still developing their database capabilities. Recent dates of publication for studies in Korea and Japan suggest that these 2 countries are starting to take • advantage of their national AHDB, while Australia may be decreasing its interest in the use of its AHDB for antidepressants. (pattern) ("*pattern*" OR "utili*ation*" OR "*therapeutic use*" OR "prescription") AND la.exact("English") 4,037,784 § #5 (burden) ("*burden*" OR "*hospital*" OR "*visit*" OR "*economic*" OR "*resource*") AND la.exact("English") 9,391,463 § #6 (cost) "*cost*" AND la. A total of 40 studies were identified, published either as articles or posters, with 16 for Australia, 14 for Taiwan, 7 • for Korea, 3 for Japan and 0 for Singapore (Table 1b) . Studies published as both poster and article are counted once only. 
Databases used
The • National Pharmaceutical Benefits Scheme (PBS) administrative database was used for all studies, except for one study on treatment patterns in elderly patients done in the Veteran Affairs Pharmacy Claims Database and one study on resource use done in the Australia's National Hospital Morbidity Database.
Topics of interest
Studies done in Australia mainly focused on treatment patterns; the objective of these studies was to document use over • time in different age groups, prescription rate, type of AD used, combination of AD, and comparison with other countries. In some instances, the database analysis was coupled with semi-structured interviews or with data from national surveys. Several studies investigated the quality of medicine prescribing, notably with regards to the National Prescribing Service (NPS) interventions. Interestingly, one study ), intended to verify if prescriptions of one class of AD (Selective Serotonin Reuptake Inhibitors, SSRIs) as observed in routine practice was consistent with the theoretic prescription pattern on which the Australian government had decided to include the class in the subsidy list.
Conclusion
Several studies were based on use of AHDB for AD / depression in Australia, all published in the 2000s. This is consistent with • the size of Australia and the number of accessible AHDB, although PBS is almost exclusively used. 
KOREA
Topics of interest
Interestingly, there were studies in Korea to document all topics of interest. • For Treatment Pattern, the 4 studies aimed to document the clinical reality of prescribing AD, highlighting low persistence to • treatment and high use of psychotropic drugs. Three of these studies were connected and evidenced how treatment adherence was associated with a lower switch rate and later on, how switch was associated with an increased chance of relapse of depression. This analysis was the basis for a cost-effectiveness (CE) study based on real life outcomes of adherence and persistence to treatment. The resource use study focused on serious outcomes of depression such as psychiatric hospitalization, psychiatric emergency • room visit, or suicide attempt and shows this is increased with combination of AD (compared to AD monotherapy) and increased with tricyclic antidepressants (TCA) compared to newer generation of AD. Finally, the burden of depression was calculated using the HIRA database to estimate direct medical costs, highlighting the • huge impact of productivity costs.
Conclusion
Although few studies were published for Korea, they documented our 3 topics of interest and evidence clinical reality facts • of relevance from a public health perspective, linking treatment patterns to resource use and cost of depression. The recent years of publication, and the high proportion of posters within the identified studies suggest there may be more publications on the HIRA database in coming years.
TAIWAN Articles Selected
A total of 14 articles/posters were identified, (1 analysis presented both as article and poster is counted as one). 
Databases used
The Taiwan National Health Institute • Research Database (NHI RD) was used for all studies except one, which used a hospital database to analyse prescription patterns in a specific sub-group of patients.
Topics of interest
The analyses in Taiwan presented the broadest coverage of topics of interest. • Analysis of Treatment Pattern was the most prominent topic analysed, showing low treatment rates, although increasing • over time, and presenting specific analysis for sub-groups by age (adolescent or elderly) or comorbid diseases, as well as prescribing behaviour. Early adherence to treatment was shown to be associated with treatment success and less relapse. Retention of patients in • the national database allowed evolution of trends over periods of up to 12 years. Interestingly, the impact of implementing the guideline on the use of BZD could be studied by comparing before -after treatment patterns and was shown to have no impact on the use of BZD in depressed patients.
One study, analysing the use of Traditional Chinese Medicine (TCM) in Taiwan, combined all topics of interest, showing that • >40% depressed patients use TCM, notably those with fewer psychiatric service contacts. TCM services represented 30% of costs of psychiatric out-patient. Costs studies analysed both the burden of depression and that of comorbidities, and also calculated the CE of the various • classes of AD. The treatment of depression, was shown to be high, and greater attention by public health officials was called in order to avoid the already significant burden of this disease on both patients and society.
Conclusion
Taiwan presented the highest number of publications, and broadest coverage of subjects within our topics of interest. Studies • were characterised by variety of subjects analysed, high level methodology, and large span of time. They allowed to evidence clinical reality facts of relevance from a public health perspective. The large number of publication in the recent 4 years is a good indication of the dynamics observed research and is a good example for the rest of the region on use of AHDB for public health research.
JAPAN
Articles Selected A total of 3 articles were identified (one article also presented as poster).
•
The articles were published between 2007 and 2013.
The 3 articles focused on Treatment Patterns.
• Databases used
The Japan Medical Data Center • (JMDC) database was used for the most recent studies, while a specific hospital database was used in 2007.
Topics of interest
Studies conducted in Japan exclusively focused on treatment patterns with the objective of verifying if treatment patterns in • clinical reality comply with guideline recommendation, notably with concerns on the use of benzodiazepine (BZD) in addition or in lieu of AD. Authors highlighted the challenge of such an approach: "On the one hand, guidelines need to reflect the real-world practices; on the other hand clinicians should limit their treatment options and allow evidence-based comparative effectiveness research among them so that patients shall no longer be given less effective and more effective treatments without being able to distinguish among them".
Conclusion
Very few studies were published in Japan considering the size of the country and the large number of AHDBs accessible.
•
The published studies documented the clinical reality of prescribing AD and BZD. Interestingly, none described resource use or cost of depression, while an analysis on the cost of depression, published in 2005 was based on the World Mental Health Japan Survey. This limited number of publications may be explained as the search focused on articles in English and/or maybe because HTA and HEOR assessment is not currently part of the reimbursement process. However, these studies were recently published, suggesting that analyses of AHDB may be taking off in Japan. Further work may therefore be expected in the coming few years.
Country
# Search Methodology -Key words Results Selected
Australia #10 #9 AND "*australia*" 11,826°n/a #11 #10 AND ("pharmaceutical benefits scheme" OR "PBS" OR "Western Australia Data Linkage" OR "Centre for Health Record Linkage*" OR "CHeReL" OR "Health LinQ" OR "Victorian Data Linkage" or "SA_NT Datalink" or "claim* database*"))
41°16
Japan #10 #9 AND "*japan*" 5,048 n/a #11 #10 AND ("CGRN" or "MDV EBM Provider" or "Hamamatsu Medical University" or "Osaka University" or "COS*Dokkyo*" or "EMR Retrieval System*" OR "Nihon University School of Medicine Clinical Data Warehouse" OR "JMDC" OR "JammNet" OR "Diagnosis Procedure Code" OR "NHI" OR "Medi*Trend" OR "IMS NPA" OR "Nihon Chouzai Pharmacy" OR "JMIRI" OR "claim* database*") 105°3 Korea #10 #9 AND "*Korea*" 2,081°n/a #11 #10 AND ("*NHIC*" OR "*National Health Insurance Corporation*" OR "*HIRA*" OR "*Health Insurance Review Assessment*" OR "claim* database*" ) 36°7 Singapore #10 #9 AND "*Singapor*" 827 n/a #11 #10 AND ("Medisave*" OR "National Electronic Health Records*" OR "claim* database*") 1°0 Taiwan #10 #9 AND "*Taiwan*" 2,008°n/a #11 #10 AND ("*NHIRD*" OR "*National Health Insurance" OR "claim* database*") 121°14
